ONCS stock forecast
Our latest prediction for OncoSec Medical, Inc.'s stock price was made on the Jan. 31, 2020 when the stock price was at 1.96$.
In the short term (2weeks), ONCS's stock price should outperform the market by 1.82%. During that period the price should oscillate between -10.89% and +15.54%.
In the medium term (3months), ONCS's stock price should underperform the market by -2.65%. During that period the price should oscillate between -45.63% and +47.59%.Get email alerts
About OncoSec Medical, Inc.
OncoSec Medical, Inc. is a biotechnology company, which engages in designing, developing, and commercializing therapies for the treatment of cancer. Its lead product candidate, ImmunoPulse IL-12, uses an electroporation device, with the aim of reversing the immunosuppressive microenvironment in the treated tumor. The company was founded by Avtar S. Dhillon and Punit S. Dhillon on February 8, 2008 and is headquartered inPennington, NJ.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -3.84$ per share.
The book value per share is 0.62$
Three months stock forecastJan. 31, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|